Prexasertib

普瑞色替

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NamePrexasertib
Drug Alias NamePrexasertib Mesylate Monohydrate普瑞舍替Captisol enabled prexasertibPrexasertib Mesylate HydrateLY-2606368 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCheckpoint kinase 2 inhibitorsCheckpoint kinase 1 inhibitors
TargetsCheckpoint kinase 2Checkpoint kinase 1
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesNeoplasm Metastasis +[21] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesUkraine +[15] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesArray BiopharmaEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And CompanyH Lee Moffitt Cancer Center & Research InstituteThe University Of Texas MD Anderson Cancer Center +[4] 
Inactive CompaniesDana-Farber Cancer InstituteNational Cancer Institute
Active IndicationsSolid tumoursMyelodysplastic SyndromesEndometrial Neoplasms +[10] 
Inactive IndicationsNeoplasm MetastasisProstatic NeoplasmsSmall Cell Lung Carcinoma +[11] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG